USPTO serial 76113579
Reviewed by CopyMark Law Group
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
EPIGENESIS Pharmaceuticals, Inc.
Cranbury, NJ
EPIGENESIS Pharmaceuticals, Inc.
Cranbury, NJ
EPIGENESIS Pharmaceuticals, Inc.
Cranbury, NJ
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Dr. Viviana Amzel
DR VIVIANA AMZEL EPIGENESIS PHARMACEUTICALS, INC7 CLARKE DRCRANBURY, NJ 08512UNITED STATES| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Describing and providing services for scientific and medical research services, namely, screening of oligonucleotide libraries to identify active anti-sense oligonucleotides for use in pharmaceutical preparations for administration via various routes, including respiratory airways, for testing and prophylaxis and therapeutic treatment of human and non-human animal ailments that may be associated with hyper-sensitivity or hyper-responsiveness to adenosine, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in many cases are adenosine receptor associated symptoms, particularly testing, preventing and therapeutically treating respiratory, airway, pulmonary and other diseases and conditions, such as asthma, pulmonary vasoconstriction, inflammation, allergies, asthma; impeded respiration, Acute Respiratory Distress Syndrome (ARDS), renal damage and failure, ischemia, administration of certain drugs, including adenosine and other drugs for, for example, treating SupraVentricular Tachycardia (SVT), adenosine stress tests, infantile Respiratory Distress Syndrome (infantile RDS), pain, cystic fibrosis, allergic rhinitis, ___ bronchitis, pulmonary hypertension, pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary disease (COPD), as well as cancers including leukemias, lymphomas, carcinomas, and the like, e.g. colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, etc., as well as all other metastatic cancers, e.g. cancers which metastasized to the lung(s), breast and prostate | SECTION 8 - CANCELLED | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 11, 2009 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Jan 23, 2008 | CFIT | CASE FILE IN TICRS | — |
| May 24, 2006 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Dec 3, 2002 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 10, 2002 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 21, 2002 | NPUB | NOTICE OF PUBLICATION | — |
| Oct 25, 2001 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 10, 2001 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 7, 2001 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 1, 2001 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 31, 2001 | DOCK | ASSIGNED TO EXAMINER | — |